Loading
Beijing Immunoah develops antibodies that switch on the immune system against cancer, including antibodies that bind two or three targets at once. Its first registered study tests an injection given directly into tumours in advanced solid cancers.
Beijing Immunoah Pharma Tech Co., Ltd. (Beijing Immune Ark Medical Technology) was founded in 2017, according to the company, by Xin Gao, with a sister company in Denver. It focuses on agonist antibodies for cancer immunotherapy and on multi-specific antibodies built on its XFab platform; its history lists licensing agreements for 4-1BB (2017), CD40 (2018) and OX40 (2019) agonist antibodies, a first tri-specific antibody proof of concept in 2020 and a pre-A financing round in December 2020. Its registered phase 1a trial, NCT06292858, tests IMB071703 given by intratumoral injection in recurrent or metastatic advanced solid tumours at a site in Shanghai, with a start date of February 2023. Its first registered cancer trial, NCT06292858, was posted on ClinicalTrials.gov in March 2024.
Shares OX40 (TNFRSF4), CD137 (4-1BB, TNFRSF9).
Shares CD40, Monoclonal antibodies.
Shares CD40, CD137 (4-1BB, TNFRSF9), Bispecific antibodies.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/